ANGLE plc (GB:AGL) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ANGLE plc, a leading liquid biopsy company, has entered into an agreement with NuProbe to secure an exclusive global license for a next-generation sequencing (NGS) assay, enhancing the analysis of circulating tumor cells (CTCs) and ctDNA from a single blood sample. This collaboration aims to advance ANGLE’s pharma services and provide highly sensitive cancer mutation detection, which has significant implications for personalized treatment plans in oncology. The company has already demonstrated the NGS panel’s efficacy in identifying mutations across various cancer types, underscoring the potential for improved clinical outcomes.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
